FDA Sponsor Liaison Program Is Not Being Used: Are Small Biotechs Missing An Opportunity? Or Partnering More?
This article was originally published in RPM Report
FDA has noticed a perplexing – and somewhat vexing – trend among smaller, less experienced pharma companies: They are not taking full advantage of a new liaison program designed to increase sponsor/FDA communication – even when they hit roadblocks during the drug review process. FDA officials have heralded the program as one of the most important under PDUFA V. So why aren’t companies using it?
You may also be interested in...
FDA-sponsor interactions vary widely, but more meetings still seem to speed applications; Special Protocol Assessments fall out of favor.
FDA topped 40 new molecular entity approvals in 2014, leaving no doubt that the agency’s drug review group is operating at peak efficiency. But it is still far from clear that drug development is out of the doldrums.
Office of New Drugs Director John Jenkins offers his top three list of the most important elements of PDUFA V – and underscores that accountability is a two-way street.